Swiss Nordic Bio 2026: AlzeCure Pharma develops treatments for numerous CNS conditions - a recent Alzheimer's deal with Lilly made the headlines
CEO Martin Jönsson discusses AlzeCure's programs, including the gamma-secretase modulator that was out-licensed to Lilly, another recent deal with QuantumCell, and others.
Coverage brought to you by










.png)